Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Partnership On Oral IL-17 Could Be Turning Point For C4XD

May Validate Small Molecule Platform

Executive Summary

The UK drug discovery specialist has made slow progress until now, but the Sanofi deal could yield a challenger in the competitive psoriasis field.

You may also be interested in...



Dice Thinks It Holds An Ace With Oral IL-17 Inhibitor In Psoriasis

The company believes it has a potential best-in-class oral drug for psoriasis in development following positive first-in-human clinical trial data. A larger Phase II study is needed.

UK Vaccine Taskforce’s Clive Dix: IP Is A Distraction, We Need To Vaccinate The World As Fast As Possible

Clive Dix, who recently stepped down as chair of the UK Vaccine Taskforce, shares his views on its success with Scrip, why AstraZeneca has been unfairly criticized, how the UK should now share its doses with other countries, and the exciting future of vaccine technology.

UK Vaccine Taskforce’s Clive Dix: IP Is A Distraction, We Need To Vaccinate The World As Fast As Possible

Clive Dix, who recently stepped down as chair of the UK Vaccine Taskforce, shares with Pink Sheet his views on its success, why AstraZeneca has been unfairly criticized, how the UK should now share its doses with other countries, and the exciting future of vaccine technology.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144272

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel